199
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Oral Valacyclovir as Prophylaxis against Herpes Simplex Virus Reactivation During High Dose Chemotherapy for Leukemia

, , , , , , & show all
Pages 2215-2219 | Published online: 01 Jul 2009

References

  • Wingard, J.R. (1993) "Viral infections in leukemia and bone marrow transplant patients", Leukemia & Lymphoma, 11, 115 — 125.
  • Devine, S.M. and Wingard, J.R. (1994) "Viral infections in severely immunocompromised cancer patients", Supportive Care in Cancer, 2, 355 — 368.
  • Reusser, P. (1998) "Current concepts and challenges in the prevention and treatment of viral infections in immunocompro-mised cancer patients", Supportive Care in Cancer, 6, 39–45.
  • Meyers, J.D., Wade, J.C., Mitchell, C.D., Saral, R., Lietman, P.S., Durack, D.T., et al. (1982) "Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host", The American Journal of Medicine, 73, 229–235.
  • Saral, R., Burns, W.H., Laskin, O.L., Santos, G.W. and Lietman, P.S. (1981) "Acyclovir prophylaxis of herpes-simplex-virus infec-tions", The New England Journal of Medicine, 305, 63–67.
  • Hann, TM., Prentice, H.G., Blacklock, H.A., Ross, M.G., Brigden, D., Rosling, A.E., et al. (1983) "Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial", British Medical Journal, 287, 384 — 388.
  • Saral, R., Ambinder, R.F., Burns, W.H., Angelopulos, C.M., Griffin, D.E., Burke, P.J., et al. (1983) "Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study", Annals of Internal Medicine, 99, 773–776.
  • Prentice, H.G. and Hann, I.M. (1983) "Studies in the prophylaxis of herpes infections in severely immunocompromised patients using acyclovir", Schweizerische Medizinische Wochenschrift Supplemen-tum, 14, 26–29.
  • Anderson, H., Scarffe, J.H., Sutton, R.N., Hickmott, E., Brigden, D. and Burke, C. (1984) "Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial", British Journal of Cancer, 50, 45–49.
  • Engelhard, D., Morag, A., Or, R., Naparstek, E., Cividalli, G., Ruchlemer, R., et al. (1988) "Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts", Israeli Journal of Medical Science, 24, 145 — 150.
  • Lonnqvist, B., Palmblad, J., Ljungman, P., Grimfors, G., Jarnmark, M., Lerner, R., et al. (1993) "Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden", Supportive Care in Cancer, 1, 139 — 144.
  • Heimdahl, A., Mattsson, T., Dahllof, G., Lonnquist, B. and Ringden, O. (1989) "The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation", Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 68, 711–716.
  • Bergmann, O.J., Ellermann-Eriksen, S., Mogensen, S.C. and Ellegaard, J. (1995) "Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial", British Medical Journal, 310, 1169–1172.
  • Bergmann, O.J., Mogensen, S.C., Ellermann-Eriksen, S. and Ellegaard, J. (1997) "Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leuke-mia: a randomized, double-blind, placebo-controlled trial", Journal of Clinical Oncology, 15, 2269 —2274.
  • Leflore, S., Anderson, P.L. and Fletcher, C.V. (2000) "A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections", Drug Safety, 23, 131–142.
  • Wagstaff, A.J., Faulds, D. and Goa, K.L. (1994) "Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy", Drugs, 47, 153–205.
  • Farah, R.A., Aquino, V.M., Munoz, L.L. and Sandler, E.S. (1998) "Safety and cost-effectiveness of outpatient total body irradiation in pediatric patients undergoing stem cell transplantation", Journal of Pediatric Hematology (Oncology, 20, 319–321.
  • Ruiz-Arguelles, G.J., Gomez-Almaguer, D., Ruiz-Arguelles, A., Gonzalez-Llano, O., Cantu, O.G. and Jaime-Perez, J.C. (2001) "Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens", American Journal of Hematology, 66, 241–244.
  • Acosta, E.P. and Fletcher, C.V. (1997) "Valacyclovir", Annals of Pharmacotherapy, 31, 185 — 191.
  • Stein, G.E. (1997) "Pharmacology of new antiherpes agents: famciclovir and valacyclovir", Journal of the American Pharmaceu-tical Association (Washington), NS37, 157 — 163.
  • CTEP, NCI (1999) Common toxicity criteria manual, version 2.0. Pp 1–35. Bethesda: National Cancer Institute.
  • Khan, S.A. and Wingard, J.R. (2001) "Infection and mucosal injury in cancer treatment", Journal National Cancer Institute Monographs, 29, 31–36.
  • Bell, W.R., Chulay, J.D. and Feinberg, J.E. (1997) "Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204)", Medicine (Baltimore), 76, 369 — 380.
  • Rivaud, E., Massiani, MA., Vincent, F., Azoulay, E. and Coudrec, L.J. (2000) "Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient", Archives of Internal Medicine, 160, 1705 — 1706.
  • Rayani, S.A., Nimmo, CJ., Frighetto, L., Martinusen, S.M., Nickoloff, D.M., Reece, D.E., et al. (1994) "Implementation and evaluation of a standardized herpes simplex virus prophylaxis protocol on a leukemia/bone marrow transplant unit", Annals of Pharmacotherapy, 28, 852–856.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.